Daxor Announces Special Year-End Dividend

NEW YORK, NY--(Marketwire - December 1, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced that The Board of Directors has voted to declare a special year-end dividend of $1.00 per share. The dividend will be paid to shareholders of record as of December 12, 2008. The dividend will be paid on Tuesday, December 30, 2008.

The Company previously paid quarterly dividends of $0.25 per share in 2008 on August 27th and November 26th. Prior to 2008, the Company last paid a dividend in 1996.

The Company is continuing to build-out its manufacturing facilities in Oak Ridge, Tennessee which is comprised of two separate 10,000 sq. ft. buildings.

There are ongoing studies on the utilization of the BVA-100 Blood Volume Analyzer in Critical Care Medicine which are nearing completion and will be ready for submission for publication in peer reviewed medical journals. Preliminary reports have indicated that as much as 30% of patients in intensive care units who receive transfusions or are denied transfusions may be inappropriately treated. The standard surrogate tests such as the hematocrit or hemoglobin tests have been shown in a number of independent studies to be inaccurate in gauging the true blood volume status of a patient. This may result in serious complications, including the death of the patient. The BVA-100 Blood Volume Analyzer provides a measurement of the patient's blood volume to within 98% accuracy.

The Company continues its R&D efforts to work on the development of an automated total body albumin analyzer. Albumin is a major protein within the blood that can be used to help support the circulation in patients with acute blood loss. Up to the present time there has been no available instrument to measure the total amount of this important protein within the body which has resulted in significant under utilization of albumin administration in situations where it could help prevent collapsed circulation.

For more information regarding Daxor Corporation's BVA-100 Blood Volume Analyzer, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh (COO) at 212-330-8515, stephen@daxor.com or Diane Meegan (Investor Relations) at 212-330-8512, dmeegan@daxor.com.